CME Session 10
Thyroid + Oncology & Thranostics Committee
Friday, October 22, 10:45-12:15

Session Title
Radionuclide Therapies - Management of Side Effects and Complications

Chairperson
Alfredo Campennì (Messina, Italy)

Programme
10:45 - 11:14 Markus Luster (Marburg, Germany): Radioiodine Therapy in Thyroid Cancer

11:14 - 11:43 Gopinath Gnanasegaran (London, United Kingdom): Peptide Receptor Radionuclide Therapy in Neuroendocrine Tumours

11:43 - 12:12 Sarah M. Schwarzenböck (Rostock, Germany): $^{177}$Lu and $^{225}$Ac PSMA Therapy for Prostate Cancer

12:12 - 12:15 Session Summary by Chairperson

Educational Objectives
1. To understand the evolving theranostic applications of radionuclide therapies for the treatment of different tumours: differentiated thyroid cancer (DTC); neuroendocrine and prostate cancers using $^{131}$I, $^{90}$Y or $^{177}$Lu-DOTATATE/DOTATOC, $^{177}$Lu-PSMA and $^{225}$Ac-PSMA, respectively.
2. To review and highlight the role of $^{131}$I, $^{90}$Y or $^{177}$Lu-DOTATATE/DOTATOC (PRRT), $^{177}$Lu-PSMA and $^{225}$Ac-PSMA regarding efficacy, toxicity/side effects/complications and quality of life

Summary
In this CME session, we will review the current status of $^{131}$I, $^{90}$Y or $^{177}$Lu-DOTATATE/DOTATOC and radiolabeled PSMA ligands for therapy of DTC, neuroendocrine tumors and metastatic castration-resistant prostate cancer, respectively. In addition, we will discuss on efficacy, safety, side effects/complications, opportunities for our theranostics therapies and challenges for the future.

Key Words
Differentiated thyroid cancer, $^{131}$I therapy, $^{131}$I theranostic agent, Neuroendocrine tumours, PRRT, radionuclide-PSMA therapy, prostate cancer, side effects.